Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor

Journal of Physiology

Volumn 590, Issue 20, 2012, Pages 5245-5255

  Burmeister, M A ^a   Bracy, D P ^b   James, F D ^b   Holt, R M ^a   Ayala, J ^a   King, E M ^a   Wasserman, D H ^b   Drucker, D J ^c   Ayala, J E ^a  

^a BURNHAM INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DEOXYGLUCOSE; EXENDIN 9; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; RECEPTOR BLOCKING AGENT; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HORMONE RELEASE; HYPERGLYCEMIA; LIVER FUNCTION; MOUSE; MUSCLE EXERCISE; MUSCLE METABOLISM; NONHUMAN; PANCREAS FUNCTION; PRIORITY JOURNAL; REGULATORY MECHANISM; SITTING; TREADMILL EXERCISE; VEIN CATHETERIZATION;

EID: 84867448981     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.234914     Document Type: Article

References (61)

1. Adam TC & Westerterp-Plantenga MS (2004). Activity-induced GLP-1 release in lean and obese subjects. Physiol Behav 83, 459-466.
2. Ahima RS, Patel HR, Takahashi N, Qi Y, Hileman SM & Zasloff MA (2002). Appetite suppression and weight reduction by a centrally active aminosterol. Diabetes 51, 2099-2104.
3. Ahren B & Pacini G (1999). Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab 277, E996-E1004.
4. Ali S, Lamont BJ, Charron MJ & Drucker DJ (2011). Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121, 1917-1929.
5. Ayala JE, Bracy DP, Hansotia T, Flock G, Seino Y, Wasserman DH & Drucker DJ (2008). Insulin action in the double incretin receptor knockout mouse. Diabetes 57, 288-297.
6. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH & Drucker DJ (2010). Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151, 4678-4687.
7. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH & Drucker DJ (2009). The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150, 1155-1164.
8. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT & Wasserman DH (2007). Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56, 1025-1033.
9. Ayala JE, Bracy DP, McGuinness OP & Wasserman DH (2006). Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55, 390-397.
10. Azuma K, Radikova Z, Mancino J, Toledo FG, Thomas E, Kangani C et al. (2008). Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93, 459-464.
11. Burmeister MA, Ferre T, Ayala JE, King EM & Holt RM (2012). Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab 302, E334-E343.
12. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Penicaud L, Drucker DJ, Magnan C & Burcelin R (2008). Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57, 2577-2587.
13. Chanoine JP, Mackelvie KJ, Barr SI, Wong AC, Meneilly GS & Elahi DH (2008). GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. Obesity 16, 202-204.
14. D'Alessio DA, Kahn SE, Leusner CR & Ensinck JW (1994). Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93, 2263-2266.
15. D'Alessio DA, Prigeon RL & Ensinck JW (1995). Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44, 1433-1437.
16. Debodo RC, Steele R, Altszuler N, Dunn A & Bishop JS (1963). On the hormonal regulation of carbohydrate metabolism; studies with C14 glucose. Recent Prog Horm Res 19, 445-488.
17. Drucker DJ (2006). The biology of incretin hormones. Cell Metab 3, 153-165.
18. Egan JM, Meneilly GS, Habener JF & Elahi D (2002). Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87, 3768-3773.
19. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT et al. (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17, 1481-1489.
20. Exton JH, Friedmann N, Wong EH, Brineaux JP, Corbin JD & Park CR (1972). Interaction of glucocorticoids with glucagon and epinephrine in the control of gluconeogenesis and glycogenolysis in liver and of lipolysis in adipose tissue. J Biol Chem 247, 3579-3588.
21. Fernando P, Bonen A & Hoffman-Goetz L (1993). Predicting submaximal oxygen consumption during treadmill running in mice. Can J Physiol Pharmacol 71, 854-857.
22. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L et al. (2003). Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100, 1438-1443.
23. Gil-Lozano M, Perez-Tilve D, Alvarez-Crespo M, Martis A, Fernandez AM, Catalina PA, Gonzalez-Matias LC & Mallo F (2010). GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 151, 2629-2640.
24. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH & Rorsman P (1998). Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47, 57-65.
25. Gutniak M, Orskov C, Holst JJ, Ahren B & Efendic S (1992). Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326, 1316-1322.
26. Hirsch IB, Marker JC, Smith LJ, Spina RJ, Parvin CA, Holloszy JO & Cryer PE (1991). Insulin and glucagon in prevention of hypoglycemia during exercise in humans. Am J Physiol Endocrinol Metab 260, E695-E704.
27. Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87, 1409-1439.
28. Kinzig KP, D'Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, Murphy EK & Seeley RJ (2003). CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23, 6163-6170.
29. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C et al. (2008). Brain glucagon-like peptide 1 signalling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149, 4768-4777.
30. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E et al. (2005). Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115, 3554-3563.
31. Kraegen EW, James DE, Jenkins AB & Chisholm DJ (1985). Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol Endocrinol Metab 248, E353-E362.
32. Kreymann B, Williams G, Ghatei MA & Bloom SR (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300-1304.
33. Lavoie C, Ducros F, Bourque J, Langelier H & Chiasson JL (1997). Glucose metabolism during exercise in man: the role of insulin and glucagon in the regulation of hepatic glucose production and gluconeogenesis. Can J Physiol Pharmacol 75, 26-35.
34. MacLusky NJ, Cook S, Scrocchi L, Shin J, Kim J, Vaccarino F, Asa SL & Drucker DJ (2000). Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signalling. Endocrinology 141, 752-762.
35. Marker JC, Hirsch IB, Smith LJ, Parvin CA, Holloszy JO & Cryer PE (1991). Catecholamines in prevention of hypoglycemia during exercise in humans. Am J Physiol Endocrinol Metab 260, E705-E712.
36. Martins C, Morgan LM, Bloom SR & Robertson MD (2007). Effects of exercise on gut peptides, energy intake and appetite. J Endocrinol 193, 251-258.
37. Mendenhall LA, Swanson SC, Habash DL & Coggan AR (1994). Ten days of exercise training reduces glucose production and utilization during moderate-intensity exercise. Am J Physiol Endocrinol Metab 266, E136-E143.
38. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT & Elahi D (2001). Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24, 1951-1956.
39. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R & Schmiegel WH (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273, E981-E988.
40. Orskov C, Holst JJ & Nielsen OV (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123, 2009-2013.
41. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG & Schmitz O (1996). GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 39, 1227-1232.
42. Prigeon RL, Quddusi S, Paty B & D'Alessio DA (2003). Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285, E701-E707.
43. Rinaman L (1999). Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277, R582-590.
44. Roesch DM, Blackburn-Munro RE & Verbalis JG (2001). Mineralocorticoid treatment attenuates activation of oxytocinergic and vasopressinergic neurons by icv ANG II. Am J Physiol Regul Integr Comp Physiol Regul Integr Comp Physiol 280, R1853-R1864.
45. Ryan AS, Egan JM, Habener JF & Elahi D (1998). Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83, 2399-2404.
46. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA & Seeley RJ (2008). Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57, 2046-2054.
47. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL & Drucker DJ (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2, 1254-1258.
48. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL & Drucker DJ (1998). Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signalling. Diabetes 47, 632-639.
49. Shalev A, Ninnis R & Keller U (1998). Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 49, 221-225.
50. Steele R, Wall JS, De Bodo RC & Altszuler N (1956). Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187, 15-24.
51. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M & Sheikh SP (1996). Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271, R848-R856.
52. Toft-Nielson M, Madsbad S & Holst JJ (1996). The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45, 552-556.
53. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
54. Ueda SY, Yoshikawa T, Katsura Y, Usui T, Nakao H & Fujimoto S (2009). Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. J Endocrinol 201, 151-159.
55. Unger EK, Piper ML, Olofsson LE & Xu AW (2010). Functional role of c-Jun-N-terminal kinase in feeding regulation. Endocrinology 151, 671-682.
56. Vella A, Shah P, Reed AS, Adkins AS, Basu R & Rizza RA (2002). Lack of effect of exendin-4 and glucagon-like peptide-1-(7, 36)-amide on insulin action in non-diabetic humans. Diabetologia 45, 1410-1415.
57. Vilsboll T, Krarup T, Madsbad S & Holst JJ (2003). Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114, 115-121.
58. Wasserman DH (1995). Regulation of glucose fluxes during exercise in the postabsorptive state. Annu Rev Physiol 57, 191-218.
59. Wasserman DH & Cherrington AD (1991). Hepatic fuel metabolism during muscular work: role and regulation. Am J Physiol Endocrinol Metab 260, E811-E824.
60. Wasserman DH, Spalding JA, Lacy DB, Colburn CA, Goldstein RE & Cherrington AD (1989). Glucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work. Am J Physiol Endocrinol Metab 257, E108-E117.
61. Zinker BA, Lacy DB, Bracy D, Jacobs J & Wasserman DH (1993). Regulation of glucose uptake and metabolism by working muscle. An in vivo analysis. Diabetes 42, 956-965.